Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine

Bone Marrow Transplantation

Volumn 25, Issue 12, 2000, Pages 1233-1241

  Holmberg, L A ^a,b   Oparin, D V ^a   Gooley, T ^a,b   Lilleby, K ^a   Bensinger, W ^a,b   Reddish, M A ^c,d   MacLean, G D ^c   Longenecker, B M ^c   Sandmaier, B M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Biomira Inc   (Canada)

^d ID Vaccine   (United States)

Author keywords

Autologous transplant; Breast cancer; Cancer vaccine; Immunotherapy; Ovarian cancer; Sialyl Tn; Stem cell rescue

Indexed keywords

CANCER VACCINE; DETOX B; THERATOPE STN-KLH; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTHRALGIA; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; CANCER IMMUNOLOGY; CANCER STAGING; CANCER STATISTICS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAUDI CELL; DIARRHEA; DRUG EFFICACY; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GRANULOMA; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; INJECTION PAIN; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL RATE; TREATMENT OUTCOME; ULCER;

EID: 0033935785     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702430     Document Type: Article

References (35)

1. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-1317.
2. Holmberg LA, Demirer T, Rowley S et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998; 22: 651-659.
3. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
4. Bensinger WI, Schiffman KS, Holmberg L et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant 1997; 19: 1183-1189.
5. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
6. Borges E, Wiesmuller KH, Jung G, Walden P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J Immunol Meth 1994; 173: 253-263.
7. Cormier JN, Salgaller ML, Prevette T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997; 3: 37-44.
8. Kantor J, Irvine K, Abrams S et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992; 84: 1084-1091.
9. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaceinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 982-990.
10. Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-1044.
11. MacLean GD, Reddish M, Koganty RR et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993; 36: 215-222.
12. Longenecker BM, Reddish M, Koganty R, MacLean GD. Immune responses of mice and human breast cancer patients following immunisation with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann NY Acad Sci 1993; 690: 276-291.
13. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emph Tumor Immunol 1996; 19: 59-68.
14. MacLean GD, Miles DW, Rubens RD et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatmem with low-dose intravenous cyclophosphamide. J Immunother Emph Tumor Immunol 1996; 19: 309-316.
15. Longenecker BM, Reddish M, Miles D, MacLean GD. Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res 1993; 2: 151-162.
16. Thor A, Ohuchi N, Szpak CA et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986; 46: 3118-3124.
17. Reddish MA, Jackson L, Koganty RR et al. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconj J 1997; 14: 549-560.
18. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992; 10: 95-101.
19. Federici MF, Kudryashov V, Saigo PE et al. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int J Cancer 1999; 81: 193-198.
20. Ryuko K, Iwanari O, Kitao M, Moriwaki S. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas. Gynecol Oncol 1993; 49: 215-224.
21. Inoue M, Ton SM, Ogawa H, Tanizawa O. Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary. Am J Clin Pathol 1991; 96: 711-716.
22. Miles DW, Happerfield LC, Smith P et al. Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer 1994; 70: 1272-1275.
23. + lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996; 42: 303-309.
24. + activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 1995; 61: 470-474.
25. Miles DW, Towlson KE, Graham R et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996; 74: 1292-1296.
26. MacLean GD, Samuel J, Meikle A et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 1992; 11: 292-305.
27. Henningsson CM, Selvaras S, MacLean GD et al. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo. Cancer Immunol Immunother 1987; 25: 231-241.
28. Galli-Stampino L, Meinjohanns E, Frische K et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 1997; 57: 3214-3222.
29. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUCI mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nature Med 1998; 4: 43-49.
30. Storek J, Witherspoon RP. Immunological reconstitution after hemopoietic stem cell transplantation. In: Atkinson K (ed). Clinical Bone Marrow and Blood Stem Cell Transplantation: A Reference Textbook. Cambridge University Press: Cambridge, UK, 2000, pp 111-146.
31. Sandmaier BM, Oparin DV, Holmberg LA et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with theratope STn-KLH cancer vaccine. J Immunother 1999; 22: 54-66.
32. Gutierrez-Delgado F, Holmberg L, Maloney D et al. High-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as consolidation for noninflammatory high-risk (HR) breast cancer. Program/Proceedings of American Society of Clinical Oncology, 35th Annual Meeting 1999; 18: 83a (Abstr.)
33. Barra A, Cordonnier C, Preziosi MP et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992; 166: 1021-1028.
34. Witherspoon RP, Matthews D, Storb R et al. Recovery of in vivo cellular immunity after human marrow grafting: influence of time postgrafting and acute graft-versus-host disease. Transplantation 1984; 37: 145-150.
35. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation (review). Bone Marrow Transplant 1990; 5: 209-226.